Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. - Wikidata - awgldk - TriplyDB

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.

http://www.wikidata.org/entity/Q37274874

about

Tuberculosis vaccines: beyond bacille Calmette-Guerin The Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine Tuberculosis Tuberculosis vaccines and prevention of infection Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy Mucosal resident memory CD4 T cells in protection and immunopathology Prime-boost approaches to tuberculosis vaccine development Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge Global gene transcriptome analysis in vaccinated cattle revealed a dominant role of IL-22 for protection against bovine tuberculosis Protection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in Cattle Mycobacterium bovis Infection of Cattle and White-Tailed Deer: Translational Research of Relevance to Human Tuberculosis Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data Effects of vaccination against paratuberculosis on tuberculosis in goats: diagnostic interferences and cross-protection Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A Simultaneous immunization against tuberculosis Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.Th17 cytokines and vaccine-induced immunity.Assessment of BCG and inactivated Mycobacterium bovis vaccines in an experimental tuberculosis infection model in sheep.Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A Dual neonate vaccine platform against HIV-1 and M. tuberculosis.Regulation of Mycobacterium-specific mononuclear cell responses by 25-hydroxyvitamin D3.Transcriptional profiling of disease-induced host responses in bovine tuberculosis and the identification of potential diagnostic biomarkers.Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.Tuberculosis immunity: opportunities from studies with cattle Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.Immunity, safety and protection of an Adenovirus 5 prime--Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves.Identification of surrogates and correlates of protection in protective immunity against Mycobacterium bovis infection induced in neonatal calves by vaccination with M. bovis BCG Pasteur and M. bovis BCG Danish.Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.Development of an unbiased antigen-mining approach to identify novel vaccine antigens and diagnostic reagents for bovine tuberculosis.Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice.Efficacy of a vaccine formula against tuberculosis in cattle.

P2860

Q22242669-420D3487-C3EA-4F09-9FDE-3E441B3249A9 Q26740410-AFAE80B3-23A3-4FC2-A1AC-053A3C3412E5 Q26782022-71A636BC-6A1D-4CC9-B6AF-CF9AE6A39EC1 Q26798372-64F1FF53-92E0-40EC-83FD-1BE012D5FF1D Q26823137-4D81978A-541A-487E-92DF-D2AC7DA2C9DA Q27024526-4E5019F2-EEEB-4B40-B791-3C8F2C9F5930 Q27309052-67D443B8-DD96-42D1-858F-4C7402832F0B Q27327288-23232FF9-1BC2-4048-80D8-377028E50C26 Q27331427-F3DB61CB-3862-4261-8EE8-06E94D7DB94F Q27339262-8E6716BA-8BE4-48E6-8596-C301F3C6B3A6 Q27346370-9B5FFB0F-2063-484C-B66A-30A41347C304 Q28083909-3E61511F-F43D-4381-B710-69C038BFE80F Q28088745-F49A2492-D774-43DE-B0F4-6CACC2BD164A Q28383049-89110C49-687D-4A2D-9564-29591D664B04 Q28710427-CE00640E-9CF0-46E5-84D6-552EB933BC15 Q28730427-C8F7536E-A7FE-4A4E-BE5D-A833E6D00B12 Q28740954-6FC5E1D3-7750-4341-BEBD-96BBA8543065 Q28742666-7ED9DE30-3A2A-4726-B167-FCE5399A0E82 Q29620144-E8C0B987-2A21-4714-B8AF-89C5EE67BF3C Q30227121-266BD9BB-8FC1-4915-BF00-F2555FFC7B84 Q33518452-2A891FED-F3E0-4484-B75E-A127427E92B6 Q33623697-F507F3DF-BDFE-4B4D-909F-4D85E2C0E2C8 Q33792227-534582FC-BFBE-48AE-8EC5-8C1744FBD2FD Q33874162-C921E4F4-89A3-4978-94F8-E02B0D328181 Q33899366-996BF243-E32B-46E7-AC54-E13FD59F2489 Q33908584-CF625CCE-5457-4F77-B693-64669F75CEED Q33955263-D3056D74-CCAD-445E-958A-F152977E2089 Q34168041-774BA7EF-A56B-4040-B247-252B683B79F9 Q34290885-C82487D5-3EF4-4A78-86DD-F9A097E5270F Q34395523-D61C08E5-CF03-45C7-922D-EDAA0479EFD8 Q34416986-2BA210FB-371D-4C22-9DC5-11BAEB1991DF Q34529382-01AA740A-024E-4106-A29A-E9B5B7413C46 Q34531535-5757AAAD-F4B8-43DF-B908-49DD9A1A31F7 Q34643320-08D332F4-CFD8-404B-BE45-4A504D31643D Q34739101-354F49D6-F9C3-4445-A9FF-408872083694 Q34806664-E2868272-62C4-4151-A0FE-08BF83566590 Q34975996-D7EFDA7F-DE7A-45F7-8223-7432A13B620F Q34983688-6F63A718-3A3A-4047-A5E0-D3E610C94B60 Q35032532-D301AB91-6F2D-4429-A00A-64CE7429733E Q35034673-CE1F1F6A-2AB5-442A-A970-00A451DB461A

P2860

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.

http://www.wikidata.org/entity/Q37274874

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Viral booster vaccines improve ...... n against bovine tuberculosis.

@en

Viral booster vaccines improve ...... n against bovine tuberculosis.

@nl

type

label

Viral booster vaccines improve ...... n against bovine tuberculosis.

@en

Viral booster vaccines improve ...... n against bovine tuberculosis.

@nl

prefLabel

Viral booster vaccines improve ...... n against bovine tuberculosis.

@en

Viral booster vaccines improve ...... n against bovine tuberculosis.

@nl

P1433

Q37274874-081D9236-8D3B-4F9B-83F7-B2E3782840B4

P1476

Q37274874-1D502288-8756-455E-9AB7-7D00879DC607

P2093

Q37274874-015A1464-17C3-4935-A139-867A3743DE1B

Q37274874-6268FDFC-A0AD-4835-8BD8-154BEFDE15C0

Q37274874-6EEA6971-6190-4152-9EF2-50E158E4E6CF

Q37274874-BD000869-5A24-4BA7-B22D-206C66F117E5

Q37274874-D8D53712-6537-49C5-B8DE-878B0CF4A6E0

Q37274874-E519E907-D305-4DCA-8982-6F8AB6F83721

Q37274874-E7404540-77AE-49F0-9383-49221763DBB1

P2860

Q37274874-0A6B8B71-A5DE-45E5-A82E-AFC291CC9BB3

Q37274874-103A5F29-8D99-42E9-A79A-C0C6FF67D3F5

Q37274874-173A1A41-C599-4EA5-A38E-806062909C21

Q37274874-18183210-6C96-4434-A3F9-3BE6FA0050F2

Q37274874-183C50D8-5FBA-4413-BB66-857F38E1C620

Q37274874-1E9DB2BE-2AED-489E-828B-D1A8902C8627

Q37274874-2246745A-BA45-4C49-B032-451FBB1B4CE0

Q37274874-24DE0C18-CB81-49DB-9FAE-ABDC5C4241D3

Q37274874-325A7C8B-3723-47D3-978F-75C13EF5BA79

Q37274874-4F9C1050-33B9-4904-A72A-A13502AE611C

P304

Q37274874-DC9918E3-38C5-4909-91F6-0C0AF3B93439

P31

Q37274874-ADAE49C9-E173-43F9-B416-6A1BAF2BDBE3

P356

Q37274874-876E4A82-7325-4C9A-A16B-51B678088101

P407

Q37274874-4B3CF8EA-658E-4C99-923B-BD9850BE36A8

P433

Q37274874-25068975-9406-40B0-BFB5-7FFCA90994FB

P478

Q37274874-1F5B0563-D324-43BD-9953-2C7350536ADD

P50

Q37274874-4DB89186-AE85-4733-A8F9-63E600459A28

Q37274874-57B64707-12BF-440F-B9AC-00652067CE63

Q37274874-B483D66D-0FBB-47B3-B50A-76E4AA6A4308

Q37274874-D3330D9A-7BF9-44B4-8133-5B63A3900298

P577

Q37274874-BC727769-DEA7-47C1-A383-ABEFA8EC1BDE

P698

Q37274874-D2EA1696-D13B-4DE9-A25F-37B8C2FBBD1E

P921

Q37274874-634E9FB3-E0F4-4E77-B59F-2D1FE3F6A404

Q37274874-CB37EB01-3F38-4C21-BD00-7D2784F6941E

P932

Q37274874-AE04E91D-1C9A-4F79-85FF-A850010A84A0

P356

P1433

Infection and Immunity

P1476

Viral booster vaccines improve ...... n against bovine tuberculosis.

@en

P2093

Bernardo Villarreal-Ramos

http://www.w3.org/2001/XMLSchema#string

H Martin Vordermeier

http://www.w3.org/2001/XMLSchema#string

Martin McAulay

http://www.w3.org/2001/XMLSchema#string

Paul J Cockle

http://www.w3.org/2001/XMLSchema#string

R Glyn Hewinson

http://www.w3.org/2001/XMLSchema#string

Shelley G Rhodes

http://www.w3.org/2001/XMLSchema#string

Zhou Xing

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa

T-cell quality in memory and protection: implications for vaccine design

Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.

Antigen specificity in experimental bovine tuberculosis.

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.

P304

3364-3373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.00287-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

Adrian V. S. Hill

Sarah Catherine Gilbert

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19487476

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

Mycobacterium tuberculosis

P932

2715681

http://www.w3.org/2001/XMLSchema#string